Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah K Meredith

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
BMC Medicine|October 28, 2017
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosisMichael E Murphy, Patrick P J Phillips, Carl M Mendel, et al.
The New England Journal of Medicine|March 14, 2019
A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisAndrew J Nunn, Patrick P J Phillips, Sarah K Meredith, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Global Health|December 24, 2022
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trialLaura Rosu, Jason J Madan, Ewan M Tomeny, et al.
Lancet (London, England)|November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
BMC Medicine|October 28, 2017
Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosisMichael E Murphy, Patrick P J Phillips, Carl M Mendel, et al.
The New England Journal of Medicine|March 14, 2019
A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisAndrew J Nunn, Patrick P J Phillips, Sarah K Meredith, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
The Lancet. Global Health|December 24, 2022
Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trialLaura Rosu, Jason J Madan, Ewan M Tomeny, et al.
Lancet (London, England)|November 11, 2022
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Sarah K Meredith, Andrew J Nunn, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Pageof 2